Background/Aims: Persons with occult-reduced estimated glomerular filtration rate (eGFR <60 ml/min/1.73 m2 detected by serum cystatin C but missed by creatinine) have high risk for complications. Among persons with preserved kidney function by creatinine-based eGFR (eGFRcreat >60 ml/min/1.73 m2), tools to guide cystatin C testing are needed. Methods: We developed a risk score to estimate an individual's probability of reduced eGFR by cystatin C (eGFRcys <60 ml/min/1.73 m2) in The Reasons for Geographic and Racial Differences in Stroke (REGARDS) study and externally validated in the Third National Health and Nutrition Examination Survey (NHANES III). We used logistic regression with Bayesian model averaging and variables available in practice. We assessed performance characteristics using calibration and discrimination measures. Results: Among 24,877 adults with preserved kidney function by creatinine, 13.5% had reduced eGFRcys. Older and Black participants, current smokers and those with higher body mass index, lower eGFRcreat, diabetes, hypertension and history of cardiovascular disease were more likely to have occult-reduced eGFR (p < 0.001). The final risk function had a c-statistic of 0.87 in REGARDS and 0.84 in NHANES. By risk score, 72% of occult-reduced eGFR cases were detected by screening only 22% of participants. Conclusions: A risk score using characteristics readily accessible in clinical practice can identify the majority of persons with reduced eGFRcys, which is missed by creatinine.

Keywords:
Kidney disease, Serum cystatin C, Creatinine, Creatinine-based estimated glomerular filtration rate, Cystatin C-based estimated glomerular filtration rate
1.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305.
2.
KDIGO: KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1-150.
3.
Shlipak MG, Matsushita K, Ärnlöv J, et al: Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med 2013;369:932-943.
4.
Peralta CA, Shlipak MG, Judd S, et al: Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA 2011;305:1545-1552.
5.
Peralta CA, Weekley CC, Li Y, Shlipak MG: Occult chronic kidney disease among persons with hypertension in the United States: data from the National Health and Nutrition Surveys 1988-1994 and 1999-2002. J Hypertens 2013;31:1196-1202.
6.
Howard VJ, Cushman M, Pulley L, et al: The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology 2005;25:135-143.
7.
Shlipak MG, Sarnak M, Katz R, et al: Cystatin-C and risk for mortality and cardiovascular disease in elderly adults. N Engl J Med 2005;352:2049-2060.
8.
Inker LA, Schmid CH, Tighiouart H, et al: Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012;367:20-29.
9.
Hastie T, Tibshirani R: Generalized Additive Models. CRC Press, 1984.
10.
Hoeting JA, Madigan D, Raftery AE, Volinsky CT: Bayesian model averaging: a tutorial. Stat Sci 1999;14:382-417.
11.
Sullivan LM, Massaro JM, D'Agostino RB Sr: Presentation of multivariate data for clinical use: the Framingham study risk score functions. Stat Med 2004;23:1631-1660.
12.
Peralta CA, Katz R, Sarnak MJ, et al: Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol 2011;22:147-155.
13.
James PA, Oparil S, Carter B, et al: Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth Joint National Committee (JNC 8). JAMA 2014;311:507-520.
14.
Knight EL, Verhave JC, Spiegelman D, et al: Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004;65:1416-1421.
15.
Chew-Harris JS, Florkowski CM, George PM, Elmslie JL, Endre ZH: The relative effects of fat versus muscle mass on cystatin C and estimates of renal function in healthy young men. Ann Clin Biochem 2013;50:39-46.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.